Therapeutic sequencing in inflammatory bowel disease: Determining the optimal position of vedolizumab for long‐term Crohn’s disease control using real‐world evidence

Documenti analoghi

• The Impact of Ustekinumab Biosimilar on Therapeutic Strategies in Crohn's Disease: A Paradigm Shift?
  di: C. Bezzio, et al.
  Pubblicazione: (2024)
• Defining mucosal healing in randomized controlled trials of inflammatory bowel disease: A systematic review and future perspective
  di: Tommaso Lorenzo Parigi, et al.
  Pubblicazione: (2024)
• Initiation of vedolizumab did not provoke new‐onset spondylarthritis in patients with inflammatory bowel disease: A prospective 24‐week study with imaging assessments
  di: Sherry Rohekar, et al.
  Pubblicazione: (2024)
• Decision‐analytic models based on real‐world data to assess treatment sequencing in inflammatory bowel disease: A complementary approach to clinical trials
  di: Nicolas Benech, et al.
  Pubblicazione: (2024)
• Expanding ultrasound horizons in inflammatory bowel disease: Beyond the bowel
  di: Paula Sousa, et al.
  Pubblicazione: (2024)